Friday, June 24, 2016

EpiBiome Finds $1M In Debt Funding

San Francisco-based EpiBiome, which is developing drugs to avoid issues with antibiotic resistant pathogens in the agricultural industry, has raised $1M in a debt financing round, the company said Thursday. The funding came from Silicon Valley Bank. The company said the funding will go towards advancing its drug development, as well as purchasing additional lab equipment for its facilities. Epibiome is backed by Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group.